Generali Investments CEE investicni spolecnost a.s. Acquires 4,797 Shares of Biogen Inc. $BIIB

Generali Investments CEE investicni spolecnost a.s. increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 12.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 43,552 shares of the biotechnology company’s stock after acquiring an additional 4,797 shares during the period. Generali Investments CEE investicni spolecnost a.s.’s holdings in Biogen were worth $7,665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Convergence Investment Partners LLC acquired a new position in Biogen during the third quarter worth $1,342,000. Caprock Group LLC acquired a new stake in shares of Biogen in the 3rd quarter valued at $742,000. Pitcairn Co. bought a new stake in shares of Biogen in the 2nd quarter worth about $936,000. Fluent Financial LLC bought a new stake in shares of Biogen in the 3rd quarter worth about $3,578,000. Finally, Leuthold Group LLC acquired a new stake in shares of Biogen during the 3rd quarter worth about $3,294,000. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of BIIB stock opened at $183.84 on Friday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm’s 50 day moving average is $185.36 and its 200-day moving average is $170.05. The firm has a market capitalization of $26.98 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 1.52 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the company posted $3.44 EPS. Biogen’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BIIB. Stifel Nicolaus lifted their price target on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Mizuho raised their price objective on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Piper Sandler raised their price objective on shares of Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Royal Bank Of Canada lifted their target price on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research note on Monday, February 9th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Biogen presently has an average rating of “Hold” and an average price target of $205.31.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.